Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lily, O
Right arrow Articles by Ford, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lily, O
Right arrow Articles by Ford, H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 12, No. 6, 808-813 (2006)
DOI: 10.1177/1352458506070946
© 2006 SAGE Publications

Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment

O Lily

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK, oliver.lily{at}leedsth.nhs.uk

E McFadden

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

E Hensor

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

M Johnson

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

H Ford

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

Disease specific quality of life was measured in the Leeds Multiple Sclerosis (MS) Treatment Programme (n-/210) using the self-report Leeds MS Quality of Life (LMSQoL) scale. The results showed a significant and sustained increase in quality of life associated with ‘disease modifying’ treatment. This contrasts with the Expanded Disability Status Scores (EDSS), which showed no measurable improvement. An increase in the LMSQoL score did not correlate with baseline age, disease duration, disability or number of prior relapses. There was no significant difference in treatment effect between relapsing-remitting and secondary progressive MS patients, or between patients receiving different products. However, patients with a poor quality of life at baseline showed the most benefit from treatment. Those who had their treatment stopped due to progression, side-effects or lack of effect had significantly lower LMSQoL scores on treatment. In this study, the LMSQoL scale was responsive to change and was easy to administer in a clinical setting.

Key Words: beta-interferon • Expanded Disability Status Scores • glatiramer acetate • Leeds MS Quality of Life scale • multiple sclerosis • quality of life

References

  • The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285 .[Abstract]
  • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AMet al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol 1996; 39: 285-294 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RPet al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group . Neurology 1995; 45: 1268-1276 .[Abstract]
  • Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPEC-TRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results . Neurology 2001; 56: 1496-1504 .[Abstract/Free Full Text]
  • Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis . Neurol Sci 2003; 24: S265-S267 .[Medline] [Order article via Infotrieve]
  • National Institute of Clinical Excellence. Beta-interferon and glatiramer acetate for the treatment of multiple sclerosis. 2002. Retrieved from www.nice.org.uk
  • Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. Health Service Circular , 2002.
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS) . Neurology 1983; 33: 1444-1452 .[Abstract/Free Full Text]
  • Noseworthy JH. Clinical scoring methods for multiple sclerosis . Ann Neurol 1994; 36: S80-S85 .[Medline] [Order article via Infotrieve]
  • Thompson AJ, Hobart JC. Multiple sclerosis: assessment of disability and disability scales . J Neurol 1998; 245: 189-196 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JHet al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort . Neurology 2004; 62: 601-606 .[Abstract/Free Full Text]
  • Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group . Neurology 1990; 40: 971-975 .[Abstract/Free Full Text]
  • Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MFet al.IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS . Neurology 2002; 59: 679-687 .[Abstract/Free Full Text]
  • Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon-beta 1a (Avonex) treatment . Mult Scler 2002; 8: 377-381 .[Abstract/Free Full Text]
  • Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin Let al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a . J Neurol Sci 2003; 216: 113-118 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Isaksson AK, Ahlstrom G, Gunnarsson LG. Quality of life and impairment in patients with multiple sclerosis . J Neurol Neurosurg Psychiatry 2005; 76: 64-69 .[Abstract/Free Full Text]
  • Nicholl CR, Lincoln NB, Francis VM, Stephan TF. Assessing quality of life in people with multiple sclerosis . Disabil Rehabil 2001; 23: 597-603 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis . Clin Rehabil 2001; 15: 247-258 .[Abstract/Free Full Text]
  • Ford HL, Gerry E, Johnson MH, Tennant A. Health status and quality of life of people with multiple sclerosis . Disabil Rehabil 200; 23: 516-521 .
  • Ford HL, Eyres S, Tennant A. Measuring change in multiple sclerosis: responsiveness of three outcome measures . J Neurol Sci 2001; 187: S456-S456 .
  • Greenhalgh J, Ford H, Long AF, Hurst K. The MS symptom and impact diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis . JNNP 2004; 75: 577-582 .[Abstract/Free Full Text]
  • Sullivan LM, D’Agostino RB Sr. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials . Stat Med 2003; 22: 1317-1334 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Walters SJ, Campbell MJ, Lall R. Design and analysis of trials with quality of life as an outcome: a practical guide . J Biopharm Stat 2001; 11: 155-176 .[CrossRef][Medline] [Order article via Infotrieve]
  • Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing . Lancet Neurol 2005; 4: 556-566 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D’Amico Ret al. Interferon in relapsing-remitting multiple sclerosis . Cochrane Database Syst Rev 2001; (4): CD002002.
  • Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RMet al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group . Ann Neurol 2000; 48: 885-892 .[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • White AT, Petajan JH. Physiological measures of therapeutic response to interferon beta-1a treatment in remitting-relapsing MS . Clin Neurophysiol 2004; 115: 2364-2371 .[CrossRef][ISI][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lily, O
Right arrow Articles by Ford, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lily, O
Right arrow Articles by Ford, H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?